This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: Piramal Enterprises Limited, Piramal Life Sciences Limited. Active years: 2009-2014.
Company Filing History:
Years Active: 2009-2014
Title: Nilesh Dagia: Innovator in Pharmaceutical Chemistry
Introduction
Nilesh Dagia is a prominent inventor based in Mumbai, India, known for his significant contributions to pharmaceutical chemistry. With a total of four patents to his name, he has made strides in developing compounds that target critical signaling pathways involved in various diseases, particularly cancer and inflammation.
Latest Patents
Among his latest innovations are the imidazopyridine derivatives, which are designed to inhibit key pathways mediated by phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR), and other critical factors. These compounds are particularly relevant in the treatment of cancer and inflammatory diseases. Another notable patent involves pyridyl derivatives, which also target PI3K and mTOR pathways, offering potential therapeutic benefits for conditions caused by the deregulation of these signaling pathways.
Career Highlights
Nilesh Dagia has worked with reputable organizations such as Piramal Life Sciences Limited and Piramal Enterprises Limited. His experience in these companies has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in pharmaceutical development.
Collaborations
Some of his notable coworkers include Asha Adrian Kulkarni-Almeida and Sapna Parikh, who have worked alongside him in various projects aimed at advancing pharmaceutical innovations.
Conclusion
Nilesh Dagia's work exemplifies the impact of innovative research in the pharmaceutical industry. His patents reflect a commitment to addressing critical health challenges through scientific discovery and collaboration.